{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:27:19Z","timestamp":1762522039234,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,5,28]],"date-time":"2017-05-28T00:00:00Z","timestamp":1495929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,28]],"date-time":"2017-05-28T00:00:00Z","timestamp":1495929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s10067-017-3693-7","type":"journal-article","created":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T22:32:25Z","timestamp":1495924345000},"page":"1569-1577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Patompong","family":"Ungprasert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia J.","family":"Erwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,28]]},"reference":[{"key":"3693_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/tan.12515","volume":"85","author":"I EL Mouraghi","year":"2015","unstructured":"EL Mouraghi I, Ouarour A, Ghozlani I, Collantes E, Solana R, El Maghraoui A (2015) Polymorphisms of HLA-A, -B, -Cw and DRB1 antigens in Moroccan patients with ankylosing spondylitis and a comparison of clinical features with frequencies of HLA-B*27. Tissue Antigens 85:108\u2013116","journal-title":"Tissue Antigens"},{"key":"3693_CR2","first-page":"780","volume":"42","author":"V Golder","year":"2013","unstructured":"Golder V, Schachna L (2013) Ankylosing spondylitis: an update. Aust Fam Physician 42:780\u2013784","journal-title":"Aust Fam Physician"},{"key":"3693_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG et al (2014) Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 53:650\u2013657","journal-title":"Rheumatology (Oxford)"},{"key":"3693_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ejim.2011.06.006","volume":"22","author":"A El Maghraoui","year":"2011","unstructured":"El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Int Med 22:554\u2013560","journal-title":"Eur J Int Med"},{"key":"3693_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/BOR.0b013e3283028328","volume":"20","author":"J Zochling","year":"2008","unstructured":"Zochling J (2008) Assessment and treatment of ankylosing spondylitis: current status and future directions. Curr Opin Rheumatol 20:398\u2013403","journal-title":"Curr Opin Rheumatol"},{"key":"3693_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.23275","volume":"58","author":"IH Song","year":"2008","unstructured":"Song IH, Poddubnyy DA, Rudwaleit M, Sieper J (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58:929\u2013938","journal-title":"Arthritis Rheum"},{"key":"3693_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","volume":"26","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL (2015) Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur J Int Med 26:285\u2013291","journal-title":"Eur J Int Med"},{"key":"3693_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/clc.22502","volume":"39","author":"P Ungprasert","year":"2016","unstructured":"Ungprasert P, Srivali N, Thongprayoon C (2016) Nonsteroidal anti-inflammatory drugs and risk of incident heart failure: a systematic review and meta-analysis of observational studies. Clin Cardiol 39:111\u2013118","journal-title":"Clin Cardiol"},{"key":"3693_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/BF03261999","volume":"35","author":"J Castellsague","year":"2012","unstructured":"Castellsague J, Riera-Guardia N, Calingaert B (2012) Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 35:1127\u20131146","journal-title":"Drug Saf"},{"key":"3693_CR10","volume":"28","author":"J Chen","year":"2013","unstructured":"Chen J, Veras MM, Liu C, Lin J (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 28:CD004524","journal-title":"Cochrane Database Syst Rev"},{"key":"3693_CR11","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"DO Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veteran Affairs cooperative study. Arthritis Rheum 42:2325\u20132329","journal-title":"Arthritis Rheum"},{"key":"3693_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA et al (2016) American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum 68:282\u2013298","journal-title":"Arthritis Rheum"},{"key":"3693_CR13","volume":"18","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 18:CD005468","journal-title":"Cochrane Database Syst Rev"},{"key":"3693_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","volume":"17","author":"R Landewe","year":"2015","unstructured":"Landewe R, van Tubergen A (2015) Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep 17:47","journal-title":"Curr Rheumatol Rep"},{"key":"3693_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis. John Wiley & Sons, West Sussex"},{"key":"3693_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"3693_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683\u2013691","journal-title":"J Clin Epidemiol"},{"key":"3693_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472","journal-title":"BMJ"},{"key":"3693_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","volume":"72","author":"E Pathan","year":"2013","unstructured":"Pathan E, Abraham S, Van Rossen E et al (2013) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 72:1475\u20131480","journal-title":"Ann Rheum Dis"},{"key":"3693_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"3693_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 52:582\u2013591","journal-title":"Arthritis Rheum"},{"key":"3693_CR22","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo-Ortega","year":"2005","unstructured":"Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568\u20131575","journal-title":"Ann Rheum Dis"},{"key":"3693_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","volume":"37","author":"RD Inman","year":"2010","unstructured":"Inman RD, Maksymowych WP (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37:1203\u20131210","journal-title":"J Rheumatol"},{"key":"3693_CR24","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3899\/jrheum.091043","volume":"37","author":"WP Maksymowych","year":"2010","unstructured":"Maksymowych WP, Salonen D, Inman PD, Rahman P, Lambert RGW (2010) Low-dose infliximab (3mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37:1728\u20131734","journal-title":"J Rheumatol"},{"key":"3693_CR25","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 54:2136\u20132146","journal-title":"Arthritis Rheum"},{"key":"3693_CR26","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RGW Lambert","year":"2007","unstructured":"Lambert RGW, Salonen D, Rahman P et al (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56:4005\u20134014","journal-title":"Arthritis Rheum"},{"key":"3693_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang F, Gu J, Zhu P et al (2014) Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73:587\u2013594","journal-title":"Ann Rheum Dis"},{"key":"3693_CR28","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC, van der Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis. Arthritis Rheum 58:3401\u20133412","journal-title":"Arthritis Rheum"},{"key":"3693_CR29","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","volume":"53","author":"C Bao","year":"2014","unstructured":"Bao C, Huang F, Khan MA et al (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology 53:1654\u20131663","journal-title":"Rheumatology"},{"key":"3693_CR30","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis","year":"2003","unstructured":"Davis JC, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230\u20133236","journal-title":"Arthritis Rheum"},{"key":"3693_CR31","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BAC, Emery P et al (2004) Outcomes of multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594\u20131600","journal-title":"Ann Rheum Dis"},{"key":"3693_CR32","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Da Silva JC, Dougados M et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65:1572\u20131577","journal-title":"Ann Rheum Dis"},{"key":"3693_CR33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomized double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70:799\u2013804","journal-title":"Ann Rheum Dis"},{"key":"3693_CR34","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534\u20132548","journal-title":"N Engl J Med"},{"key":"3693_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H et al (2017) Secukinumab efficacy in anti-TNF-na\u00efve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis 76:571\u2013592","journal-title":"Ann Rheum Dis"},{"key":"3693_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of double-blind randomized placebo-controlled phase 3 study. Ann Rheum Dis 73:39\u201347","journal-title":"Ann Rheum Dis"},{"key":"3693_CR37","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Deodhar A, Wei JC et al (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomized placebo-controlled, dose-ranging study. Ann Rheum Dis","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"3693_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2217\/imt.13.10","volume":"5","author":"A Jain","year":"2013","unstructured":"Jain A, Singh JA (2013) Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 5:265\u2013299","journal-title":"Immunotherapy"},{"key":"3693_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/HRP.0000000000000025","volume":"22","author":"A Yildiz","year":"2014","unstructured":"Yildiz A, Vieta E, Correll CU, Nikodem M, Baldessarini RJ (2014) Critical issues on the use of network meta-analysis in psychiatry. Harv Rev Psychiatry 22:367\u2013372","journal-title":"Harv Rev Psychiatry"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3693-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3693-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3693-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T07:48:26Z","timestamp":1589442506000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3693-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,28]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3693-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2017,5,28]]},"assertion":[{"value":"7 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was supported by a grant (CTSA Grant Number UL1 TR000135) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}